Keywords: Bayer, BAY79-4980 recombinant Factor VIII, Research,

Bayer says Ph II BAY79-4980 recombinant Factor VIII trial will not meet primary endpoint

Article | 25 January 2010

Print This

German drug major Bayer Schering Pharma AG, Germany has announced that an independent Data Safety and Monitoring Board has completed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in